Hayfin Capital Management executed a $400 million credit facility for Amicus Therapeutics, a biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases.
Hayfin Capital Management will provide MiMedx with $75 million in debt financing, including a five-year term loan facility in the aggregate principal amount of $50 million and a one-year, delayed draw term loan facility in the aggregate principal amount of $25 million.
Hayfin Capital Management provided debt financing to support Crown Laboratories and Hildred Capital Partners’ acquisition of North American distribution rights of five OTC consumer brands from GlaxoSmithKline.
Hayfin Capital Management provided a €23 million ($27.805 million) debt facility consisting of a five-year term loan to Sinclair Pharma, an international aesthetics company.
GulfMark Offshore completed its financial restructuring plan and emerged from bankruptcy protection under Chapter 11 of the U.S. Bankruptcy Code. DNB Capital served as administrative agent for a $25 million revolver and a $100 million term loan to support the restructuring.
GB Credit Partners announced its first European transaction. The loan is part of a €75 million ($102 million) facility arranged by Hayfin Capital to ATU, and is part of a broader recapitalization between the company and its main creditors, including Centerbridge Partners and Goldman Sachs.